Gut Microbiota-Derived Metabolites Emerge as Key Modulators of Cancer Immunotherapy Efficacy
核心洞察
Gut microbiota-derived metabolites, including short-chain fatty acids (搜索) (SCFAs), bile acids, and tryptophan derivatives, significantly modulate tumor microenvironment immune responses and influence cancer immunotherapy outcomes.
SCFAs enhance CD8+ T cell function and memory formation while promoting regulatory T cell differentiation, with butyrate specifically improving anti-PD-1 (搜索) therapy efficacy through epigenetic mechanisms.
Fecal microbiota transplantation from immunotherapy responders to non-responders shows promise in converting treatment resistance, with specific bacterial strains like Akkermansia muciniphila serving as predictive biomarkers.
Emerging research reveals that gut microbiota-derived metabolites play crucial roles in modulating cancer immunotherapy responses, offering new therapeutic avenues for improving treatment outcomes. Two comprehensive reviews published in Frontiers in Immunology (搜索) highlight the complex interplay between microbial metabolites and the tumor microenvironment, particularly in non-small cell lung cancer (搜索) (NSCLC) treatment.
Metabolites as Immune System Modulators
The gut microbiota produces diverse metabolites that serve as signaling molecules between the intestinal ecosystem and tumor sites. Short-chain fatty acids (搜索) (SCFAs), primarily acetate, propionate (搜索), and butyrate, emerge as key players in this communication network. These metabolites are produced through fermentation of dietary fiber by specific anaerobic microbial communities and exhibit the highest concentrations within the gut.
Research demonstrates that SCFAs significantly influence T cell differentiation and function. Butyrate enhances CD8+ T cell responses by inhibiting histone deacetylase (HDAC (搜索)) and upregulating effector molecules, contributing to anti-tumor immune responses in colorectal and gastric cancers. The metabolite also promotes regulatory T cell (Treg) differentiation, helping maintain intestinal homeostasis while potentially affecting cancer progression.
Impact on Immunotherapy Efficacy
Studies reveal that gut microbiota composition and metabolite profiles correlate strongly with immunotherapy responses. In NSCLC patients, serum butyrate levels positively correlate with programmed cell death-1 (PD-1 (搜索)) expression on circulating CD8 T cells. Butyrate increases histone 3 lysine 27 acetylation in the promoter regions of Pdcd1 and CD28 (搜索) genes, thereby promoting PD-1/CD28 expression and enhancing anti-PD-1 therapy efficacy.
Metagenomic analyses show that favorable immunotherapy responders exhibit enhanced SCFA production pathways. In murine models, fecal microbiota transplantation (FMT) and SCFA supplementation improved therapeutic outcomes by promoting effector T cell activity within tumors.
Treatment-Induced Microbiota Changes
Standard NSCLC treatments significantly alter gut microbiota composition. Platinum-based chemotherapy increases Bifidobacterium species abundance, while pemetrexed treatment elevates Enterococcaceae, Lactobacillaceae, and Streptococcaceae populations. Concurrent chemoradiotherapy leads to increased Bacteroidetes and Proteobacteria with decreased Firmicutes.
Immune checkpoint inhibitor therapy produces distinct microbial signatures. The CAVE-LUNG (搜索) clinical trial identified increased expression of Agathobacter M104/1 and Blautia SR1/5 following cetuximab plus avelumab treatment. These changes correlate with clinical outcomes, suggesting microbiota composition as a predictive biomarker.
Therapeutic Interventions
Several microbiota-targeted interventions show promise for enhancing cancer treatment:
Probiotic Supplementation: Clostridium butyricum MIYAIRI 588 (CBM588) potentiates PD-1 (搜索) blockade efficacy by modulating gut microbiota diversity and immune responses. CBM588 supplementation enhances IL-10 secretion by lamina propria monocytes and facilitates CD8+ T cell activation.
Metabolite Supplementation: Direct SCFA supplementation demonstrates therapeutic potential. Sodium butyrate inhibits lung cancer cell growth, triggers apoptosis, and modulates immune responses through TNF receptor-associated factor 6 (TRAF6 (搜索))-thioredoxin-interacting protein (TXNIP (搜索)) pathway activation.
Fecal Microbiota Transplantation: FMT from immunotherapy responders to non-responders increases treatment response rates without increasing toxicity. Akkermansia muciniphila abundance serves as a reliable biomarker for predicting immunotherapy outcomes, with enrichment enhancing immune responses through checkpoint blockade.
Clinical Applications and Biomarkers
Baseline microbiome characteristics provide valuable prognostic information. Patients enriched with Akkermansia species show favorable prognosis during PD-1 (搜索) blockade immunotherapy. Similarly, baseline SCFA enrichment correlates with long-term immunotherapy benefits.
Multiple clinical trials are investigating microbiota-based interventions. NCT05669846 examines FMT in NSCLC patients progressing on PD-1 (搜索) therapy, while NCT06221800 analyzes gut microbiome dynamics during various treatment modalities.
Mechanisms of Action
The therapeutic effects of gut metabolites operate through multiple mechanisms. SCFAs function as epigenetic regulators, influencing gene expression through HDAC (搜索) inhibition. They also modulate immune cell metabolism, affecting T cell differentiation and macrophage polarization.
Bile acids, another important metabolite class, regulate Th17/Treg balance through specific receptor pathways. Lithocholic acid derivatives inhibit Th17 differentiation while enhancing Treg generation, contributing to immune homeostasis.
Future Directions
The field is moving toward more refined interventions, progressing from whole-stool FMT to defined microbial communities and purified metabolites. Microbial ecosystem therapy (MET) represents an intermediate strategy maintaining ecological functionality while improving safety and reproducibility.
Advanced analytical techniques, including single-cell sequencing and spatial transcriptomics, are being integrated to better understand microbiota-host interactions. These approaches will enable more precise targeting of specific microbial populations and their metabolites.
The research underscores the potential for microbiota-targeted therapies to become routine components of cancer treatment, offering personalized approaches based on individual microbiome profiles. As clinical trials progress and safety profiles are established, gut microbiota modulation may revolutionize cancer immunotherapy by enhancing efficacy while reducing adverse events.